PriceTargets.com logo

Roquefort Therapeutics - COIL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 8.50 As of 09/21/2026 10:58 AM ET
▲ +0.9 (11.84%)

This chart shows the closing price for COIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Roquefort Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COIL

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Roquefort Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 8.50.

This chart shows the closing price for COIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Roquefort Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/21/2026Shore Capital GroupReiterated RatingHouse Stock
(Data available from 9/21/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
3/25/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Roquefort Therapeutics logo
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/
Read More

Today's Range

Now: GBX 8.50
Low: 7.50
High: 8.50

50 Day Range

MA: GBX 9.21
Low: 7.49
High: 10.50

52 Week Range

Now: GBX 8.50
Low: 6.75
High: 12.50

Volume

156,529 shs

Average Volume

204,342 shs

Market Capitalization

£36.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Roquefort Therapeutics?

The following Wall Street analysts have issued research reports on Roquefort Therapeutics in the last year: Shore Capital Group Ltd.
View the latest analyst ratings for COIL.

What is the current price target for Roquefort Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Roquefort Therapeutics in the last year. has the lowest price target set, forecasting a price of £100,000 for Roquefort Therapeutics in the next year.
View the latest price targets for COIL.

What is the current consensus analyst rating for Roquefort Therapeutics?

Roquefort Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for COIL.

What other companies compete with Roquefort Therapeutics?

Other companies that are similar to Roquefort Therapeutics include Tiziana Life Sciences, Verseon, Scancell, Mereo BioPharma Group plc (MPH.L) and 4basebio. Learn More about companies similar to Roquefort Therapeutics.

How do I contact Roquefort Therapeutics' investor relations team?

Roquefort Therapeutics' physical mailing address is Eccleston Yards, 25 Eccleston Place, London SW1W 9NF, United Kingdom. The company's listed phone number is 44 20 3290 9339. The official website for Roquefort Therapeutics is www.roquefortinvest.com. Learn More about contacing Roquefort Therapeutics investor relations.